BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 31850909)

  • 1. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Cell Carcinoma With Fibromyomatous Stroma-The Whole Story.
    Shah RB
    Adv Anat Pathol; 2022 May; 29(3):168-177. PubMed ID: 35249990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
    Henske EP; Cornejo KM; Wu CL
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
    Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
    Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
    Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
    Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
    Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
    Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
    Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
    Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
    Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
    Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
    Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
    Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
    Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
    Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations?
    Parilla M; Kadri S; Patil SA; Ritterhouse L; Segal J; Henriksen KJ; Antic T
    Am J Surg Pathol; 2018 Jul; 42(7):911-917. PubMed ID: 29668487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
    Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
    Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
    Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
    Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women.
    Trpkov K; Hes O; Bonert M; Lopez JI; Bonsib SM; Nesi G; Comperat E; Sibony M; Berney DM; Martinek P; Bulimbasic S; Suster S; Sangoi A; Yilmaz A; Higgins JP; Zhou M; Gill AJ; Przybycin CG; Magi-Galluzzi C; McKenney JK
    Am J Surg Pathol; 2016 Jan; 40(1):60-71. PubMed ID: 26414221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney.
    Aydin H; Chen L; Cheng L; Vaziri S; He H; Ganapathi R; Delahunt B; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2010 Nov; 34(11):1608-21. PubMed ID: 20924276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype.
    Hakimi AA; Tickoo SK; Jacobsen A; Sarungbam J; Sfakianos JP; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Chen YB; Sankin A; Mano R; Coleman JA; Russo P; Ogawa S; Sander C; Hsieh JJ; Reuter VE
    Mod Pathol; 2015 Jun; 28(6):845-853. PubMed ID: 25676555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.